Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | SmCB2 peptidase (C01 family) | 0.0137 | 0.3598 | 0.4965 |
Echinococcus granulosus | cathepsin b | 0.0137 | 0.3598 | 0.3598 |
Plasmodium falciparum | plasmepsin II | 0.0047 | 0 | 0.5 |
Echinococcus multilocularis | tachykinin peptides receptor 99D | 0.0296 | 1 | 1 |
Echinococcus granulosus | peptidyl glycine alpha amidating monooxygenase | 0.0227 | 0.7246 | 0.7246 |
Loa Loa (eye worm) | hypothetical protein | 0.0227 | 0.7246 | 1 |
Echinococcus multilocularis | cathepsin b | 0.0137 | 0.3598 | 0.3598 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, C-terminal domain containing protein | 0.0227 | 0.7246 | 1 |
Schistosoma mansoni | peptidyl-glycine monooxygenase | 0.0227 | 0.7246 | 1 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, C-terminal domain containing protein | 0.0121 | 0.2958 | 0.365 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, N-terminal domain containing protein | 0.0061 | 0.0565 | 0.0107 |
Schistosoma mansoni | cathepsin D (A01 family) | 0.0139 | 0.3701 | 0.5108 |
Trichomonas vaginalis | Clan AA, family A1, cathepsin D-like aspartic peptidase | 0.0047 | 0 | 0.5 |
Toxoplasma gondii | aspartyl protease ASP1 | 0.0047 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin IV | 0.0047 | 0 | 0.5 |
Echinococcus multilocularis | peptidyl glycine alpha amidating monooxygenase | 0.0227 | 0.7246 | 0.7246 |
Schistosoma mansoni | peptidylglycine monooxygenase | 0.0121 | 0.2958 | 0.4082 |
Loa Loa (eye worm) | hypothetical protein | 0.0137 | 0.3598 | 0.4965 |
Echinococcus granulosus | cathepsin b | 0.0137 | 0.3598 | 0.3598 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0137 | 0.3598 | 0.4965 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0137 | 0.3598 | 0.4965 |
Trypanosoma cruzi | cysteine peptidase C (CPC), putative | 0.0137 | 0.3598 | 0.5 |
Brugia malayi | cathepsin B-like cysteine proteinase | 0.0137 | 0.3598 | 0.4598 |
Plasmodium falciparum | plasmepsin VI | 0.0047 | 0 | 0.5 |
Toxoplasma gondii | aspartyl proteinase (eimepsin), putative | 0.0047 | 0 | 0.5 |
Echinococcus multilocularis | cathepsin b | 0.0137 | 0.3598 | 0.3598 |
Loa Loa (eye worm) | hypothetical protein | 0.0121 | 0.2958 | 0.4082 |
Plasmodium falciparum | plasmepsin I | 0.0047 | 0 | 0.5 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0137 | 0.3598 | 0.4965 |
Schistosoma mansoni | cathepsin D (A01 family) | 0.0139 | 0.3701 | 0.5108 |
Plasmodium vivax | plasmepsin IV, putative | 0.0047 | 0 | 0.5 |
Schistosoma mansoni | dopamine-beta-monooxygenase | 0.0121 | 0.2958 | 0.4082 |
Plasmodium vivax | aspartyl proteinase, putative | 0.0047 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 0 | Compound was evaluated for its ability to block conditioned avoidance response (CAR) in rats; Dose administered perorally is 40 mg/kg; no sinificant block 0-25% | ChEMBL. | 6105217 |
Activity (functional) | = 0 | compound was evaluated for its ability to produce catalepsy activity in rats; Dose administered perorally is 50 mg/kg | ChEMBL. | 6105217 |
EDmin (functional) | = 200 mg kg-1 | Hypothermia in mice after perorla administration | ChEMBL. | 6105217 |
EDmin (functional) | = 200 mg kg-1 | Hypothermia in mice after perorla administration | ChEMBL. | 6105217 |
LD50 (ADMET) | > 400 mg kg-1 | Lethal dose in mice after perorla administration | ChEMBL. | 6105217 |
LD50 (ADMET) | > 400 mg kg-1 | Lethal dose in mice after perorla administration | ChEMBL. | 6105217 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.